EGFR and lung cancer: CAR-T cells targeting EGFR variant III [229], mesothelin [230], Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) [231], Delta-like 3 (DLL3) [232], PSCA- and MUC-1 [233], and PD-L1 [234] have shown significant antitumor effects against lung cancer cells in vitro and in vivo.